Midpoint CD34 measurement as a predictor of PBPC product yield in pediatric patients undergoing high-dose chemotherapy

Rameshwar S. Sidhu, Edmund Orsini, Roger Giller, Ralph Quinones, Nicholas K. Foreman, Hannis Thompson, Brad Brimhall, Karen Walton, Melissa Croskell, Tuan N. Le

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


High-dose chemo/radiotherapy of sensitive tumors requires PBPC rescue doses of >3×106 CD34/kg (range: 3-20×106 CD34/kg). Because of the diversity of stem cell treatment protocols and clinical presentation of patients at the time of peripheral blood progenitor cell (PBPC) harvest, the use of the mid-point CD34 positive cell measurement was initiated to predict the final CD34-positive cell product yield/stem cell harvest. The measurement of CD34-positive cells at the mid-point of the initial setting of 5 total blood volumes (TBV) allows for the extension, shortening, or no change in the TBV processing to achieve a maximum goal of CD34-positive cells/kg body weight required for stem cell transplantation. The estimation of mid-point CD34-positive cells guided our center to extend 22 procedures, shorten 26 procedures, and leave 20 procedures unchanged. This investigation addresses three aspects of PBPC collection in pediatric patients: (1) the processing of large blood volumes (more than the defined 3 TBV and maximum up to 13 TBV in one session) to achieve good efficiency of the procedure; (2) the use of the mid-point CD34 measurement at 2.5 of 5 TBV initially set to predict the maximum goal of CD34 cells /kg needed on the same day of PBPC collection; and (3) PBPC collection in pediatric patients <10 kg body weight (as low as 5.8 kg body weight).

Original languageEnglish (US)
Pages (from-to)165-168
Number of pages4
JournalJournal of Clinical Apheresis
Issue number3
StatePublished - Oct 2006
Externally publishedYes


  • Leukapheresis
  • Priming
  • Rescue dose
  • Total blood volume

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Midpoint CD34 measurement as a predictor of PBPC product yield in pediatric patients undergoing high-dose chemotherapy'. Together they form a unique fingerprint.

Cite this